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Abstract
Background:  Cartilage loss is a hallmark of arthritis and follows activation of catabolic processes
concomitant with a disruption of anabolic pathways like insulin-like growth factor 1 (IGF-1). We
hypothesized that two natural products of South American origin, would limit cartilage degradation by
respectively suppressing catabolism and activating local IGF-1 anabolic pathways. One extract, derived
from cat's claw (Uncaria guianensis, vincaria®), is a well-described inhibitor of NF-κB. The other extract,
derived from the vegetable Lepidium meyenii (RNI 249), possessed an uncertain mechanism of action but
with defined ethnomedical applications for fertility and vitality.
Methods: Human cartilage samples were procured from surgical specimens with consent, and were
evaluated either as explants or as primary chondrocytes prepared after enzymatic digestion of cartilage
matrix. Assessments included IGF-1 gene expression, IGF-1 production (ELISA), cartilage matrix
degradation and nitric oxide (NO) production, under basal conditions and in the presence of IL-1β.
Results: RNI 249 enhanced basal IGF-1 mRNA levels in human chondrocytes by 2.7 fold, an effect that
was further enhanced to 3.8 fold by co-administration with vincaria. Enhanced basal IGF-1 production by
RNI 249 alone and together with vincaria, was confirmed in both explants and in primary chondrocytes (P
<0.05). As expected, IL-1β exposure completely silenced IGF-1 production by chondrocytes. However, in
the presence of IL-1β both RNI 249 and vincaria protected IGF-1 production in an additive manner (P
<0.01) with the combination restoring chondrocyte IGF-1 production to normal levels. Cartilage NO
production was dramatically enhanced by IL-1β. Both vincaria and RNI 249 partially attenuated NO
production in an additive manner (p < 0.05). IL-1β – induced degradation of cartilage matrix was quantified
as glycosaminoglycan release. Individually RNI 249 or vincaria, prevented this catabolic action of IL-1β.
Conclusion: The identification of agents that activate the autocrine production of IGF-1 in cartilage, even
in the face of suppressive pro-inflammatory, catabolic cytokines like IL-1β, represents a novel therapeutic
approach to cartilage biology. Chondroprotection associated with prevention of the catabolic events and
the potential for sustained anabolic activity with this natural product suggests that it holds significant
promise in the treatment of debilitating joint diseases.
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Background
Osteoarthritis is a painful and debilitating joint condition
that affects hundreds of millions worldwide [1,2]. Despite
the prevalence of the disease the current therapeutic
options have significant limitations. The popular non-
steroidal anti-inflammatory class of therapeutics
(NSAIDs), which block cyclo-oxygenase (COX), provide
symptomatic relief but do not abrogate the underlying
disease process [3]. Indeed, it is well appreciated that car-
tilage destruction can proceed unabated despite suppres-
sion of inflammation [4]. To this dilemma, the COX-2
specific class of NSAIDs has revealed an increase in the
risk for cardiovascular and heart disease [5,6], although
their design was an attempt to reduce complications asso-
ciated with non-specific COX inhibitors [7]. Thus the
quest to develop new therapeutic entities has taken on
greater impetus and yet additional uncertainty.
Patients often supplement pharmaceutical strategies for
managing arthritis with complementary medicines. These
may include acupuncture [8], nutraceuticals [9-11], and
botanicals [12,13]. Glucosamine and chondroitin based
products dominates the nutraceutical approach to arthri-
tis. Glucosamine and chondroitin are structural elements
of cartilage and matrix and their proposed therapeutic
benefits center on the assumption that ingestion of these
matrix elements, despite their poor absorption [14,15],
will replace matrix that is lost as a result of the catabolic
process. Not surprisingly large amounts are required and
the onset of action with this approach is on the order of
months [16-19]. The recently published GAIT study [20]
indicated that glucosamine, chondroitin as individual
treatments or in combination failed to demonstrate sig-
nificant differences from placebo in the relief of mild to
moderate osteoarthritis of the knee. This observation may
reflect that these are structural elements only and do not
directly modify the processes of joint destruction or
repair.
On the other hand botanicals, especially those with redox-
based actions, hold promise in the treatment of chronic
inflammation [21-26]. Green tea catechins, especially epi-
gallocatechin gallate (EGCG), have been shown to limit
human cartilage degradation in vitro [20,26] and main-
tain joint architecture in the collagen-induced arthritis
(CIA) animal model [26]. This anti-inflammatory action
is thought to be the result of inhibition of transcriptional
events, particularly prevention of NF-κB activation by
cytokines and oxidants. NF-κB is a critical transcription
factor in chronic inflammation and is a desirable target for
new therapeutics, including pharmaceutical develop-
ment, as it regulates numerous genes that contribute to
the inflammatory process [28-30]. Of particular note for
joint dysfunction, NF-κB regulates the production of
matrix metalloproteases (MMPs) by chondrocytes [31].
During inflammation or injury chondrocytes release
MMPs, which in turn degrade the cartilage matrix, releas-
ing glycosaminoglycans (GAG), which can then be readily
quantified as an index of catabolic events in cartilage.
Indeed, these events were reproduced in this study with
human knee cartilage explants where IL-1β treatment
causes GAG release from explants.
While the developmental pipeline for new therapeutics
has focused on symptomatic relief (NSAIDs) and
approaches to alleviate joint destruction (MMP suppres-
sion), there are few approaches that also address joint res-
toration or activation of anabolic, repair pathways. It has
been well appreciated that inflammation and infection
silences the expression of repair pathways like IGF-1
[32,33]. Concomitant with a suppression of local, auto-
crine production of IGF-1 during inflammation is an
uncoupling of the signal transduction pathways for exog-
enous Growth Hormone (GH) and IGF-1 [34-36]. This
combination of lost tissue responsiveness to circulating
levels of anabolic factors and compromised local produc-
tion results in a sustained loss of anabolic tone. For joints,
this may include supporting musculature as well as carti-
lage and bone [37]. This problem is more apparent for the
elderly where these events are superimposed on an age-
related loss in IGF-1 activity. For these reasons, Cappola et
al [38] observed that those elderly individuals with a com-
bination of high IL-6 levels and low IGF-1 levels are at the
greatest risk for enhanced morbidity and mortality.
These factors also relate to the increasing incidence of
osteoarthritis and joint dysfunction with age [39] and the
reduced growth associated with pediatric chronic inflam-
matory bowel disease, where anti-IL-6 antibodies restored
linear growth and IGF-1 levels independent of nutrition
[40]. Indeed, there appears to be excellent evidence that
growth restriction with chronic inflammation, including
arthritis, is the result of suppression of IGF-1 production
and activity, independent of GH, and in response to IL-6
[41,42]. Supplemental IGF-1 restored linear growth in
these models, linking the suppression of IGF-1 to com-
promised anabolic activity [43].
In the present study we hypothesized that a combination
of a cat's claw (Uncaria guianensis) extract devoid of
immunostimulatory oxindole alkaloids [44] and an
extract of the Andean vegetable Lepidium meyenii, may
provide the desired therapeutic innovation for compro-
mised anabolic tone. The rationale for this hypothesis
centered on our previous work with Uncaria guianensis
extract vincaria, as a potent inhibitor of NF-κB, TNFα and
associated anti-inflammatory and cytoprotective actions
[25,44-46]. Additionally, vincaria has successfully com-
pleted a small trial for osteoarthritis of the knee demon-BMC Complementary and Alternative Medicine 2006, 6:13 http://www.biomedcentral.com/1472-6882/6/13
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strating a rapid reduction in pain and improved function
[47].
Lepidium meyenii extracts had previously been demon-
strated to have pro-fertility actions [48-51], an application
that is not intuitive for treating arthritis. The pro-fertility
actions of Lepidium meyenii could not be explained on the
basis of an augmentation of sex steroid or gonadotrophin
pathways [48,49] and the mechanism underlying these
benefits has remained elusive until now. However, based
on this ethnomedical knowledge and our own observa-
tions that these extracts were anabolic in farmed fish
(unpublished reports) whose growth is critically depend-
ent on IGF-1, we hypothesized that the central mecha-
nism of action for Lepidium meyenii extracts was the
autocrine activation of IGF-1. If our hypothesis was to be
validated then this would rapidly open a new approach to
the management of arthritis.
The present study was designed to address these issues
with a focus on the functional consequences of maintain-
ing IGF-1 gene activity and production in human cartilage
explants. The study had goals of determining if RNI 249
could activate human chondrocyte IGF-1 gene expression
and maintain IGF-1 production in the face of pro-inflam-
matory signals, IL-1β, that normally silence the IGF-1
gene.
Methods
Reagents
Tissue culture medium and related reagents were pur-
chased from either Mediatech (Herndon, VA) or InVitro-
gen (Carlsbad, CA). Recombinant human IL-1β was
purchased from R&D Systems (St Paul, MN), and other
chemicals were purchased from Sigma-Aldrich (Saint
Louis, MO). The extracts, vincaria (RN180) or RNI 249,
and their combination (Reparagen™) were supplied by
Rainforest Nutritionals, Inc and were dissolved in water
and filtered through a 0.45 µm filter under vacuum prior
to use. Vincaria is an alkaloid depleted water based extract
of Uncaria guianensis that is standardized for antioxidant
activity (DPPH radical quenching) and an oxindole alka-
loid content of less than 0.1 mg/g as determined by HPLC.
RNI 249 consists of a polar extract of Lepidium meyenii that
is standardized for its DPPH quenching activity prior to
combining with an inert stabilizing material.
Human chondrocytes culture and cartilage explants
Human OA cartilage samples were procured through the
Tissue Procurement Facility of University Hospitals of
Cleveland/Case Western Reserve University and with
prior approval of the Institutional Review Board of Uni-
versity Hospitals of Cleveland. Cartilage samples were
obtained from a total of 10 subjects, 6 females and 4
males, representing several racial groups (Hispanic, Afri-
can-American and Caucasian, with a mean age of 62 yrs).
The cartilage samples were obtained from patients under-
going total arthroplasty of the knee due to degenerative
joint diseases. In all cases care was taken to use only "mac-
roscopically normal" cartilage samples. For replication of
experiments chondrocytes from age and sex matched car-
tilage samples were used. No samples were exposed to
radiation solely for the purpose of these studies but
almost all the patients will have received X-rays as part of
their clinical presentation during the execution of care.
The same donor tissue was not used in all experiments but
untreated controls were included in all protocols.
Chondrocytes were prepared by the enzymatic digestion
of knee cartilage as previously described [20,23,26].
Chondrocytes were plated (1 × 106 cells/ml) in 35 mm
culture dishes (Becton-Dickinson, Mountain View, CA,
USA) and cultured in DMEM:F12 (Mediatech, Herndon,
VA) supplemented with 10% FCS and 1% Penn:Strep for
72 hrs at 37°C and 5% CO2 in a tissue culture incubator.
Chondrocytes were serum-starved overnight and then
exposed to RNI 249 (50 µg/ml), vincaria (10 µg/ml) alone
or in combination in fresh serum-free medium for 1 hr
prior to the addition of IL-1β. Cell viability before plating
was monitored by the MTT assay (Cell Viability and Pro-
liferation Assay) according to the instructions of the man-
ufacturer (R&D Systems). In some cases, chondrocyte
viability after exposure to the different agents was deter-
mined by Trypan blue exclusion assay.
Full-thickness cartilage slices (20–25 mg) were dissected
from the cartilage using sterile scalpel blade (Feather
Safety Razor Co., Japan). Four to five cartilage pieces
(approximately equal in size and weight) were transferred
to each well of a 24-well, flat bottom plate (Nunc, Den-
mark) containing DMEM:F-12 (1:1) supplemented with
antibiotics and 10% FCS and cultured for 24 hours. Sub-
sequently the cartilage explants were cultured overnight in
serum free media. The cartilage explants were treated with
IL-1β alone or with IL-1β + vincaria or RNI 249, alone or
in combination for 72 hrs in serum free media. Explants
cultured in the absence of IL-1β, vincaria or RNI 249, were
used as controls. Additionally, the actions of RNI 249 and
vincaria singularly and together were examined independ-
ently of IL-1β exposure (5 ng/ml). Where appropriate,
explants were exposed to vincaria or RNI 249 were 15
minutes prior to the treatment with IL-1β. Total gly-
cosaminoglycan present in the culture supernatant was
estimated as described below. The doses of RNI 249 and
vincaria that were evaluated were the lowest doses dem-
onstrating effectiveness. However full dose-response
curves were not performed as the focus was on potential
additive effects and dosing that is likely to be exposed in
the clinical setting.BMC Complementary and Alternative Medicine 2006, 6:13 http://www.biomedcentral.com/1472-6882/6/13
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Quantitative RT-PCR
Total cytoplasmic RNA was prepared from primary cul-
tures of human chondrocytes using a commercially avail-
able kit according to the instructions of the manufacturer
(Qiagen, Valencia, CA). Real time quantitative RT-PCR
with internal fluorescent hybridization probes was per-
formed as previously described [22] and the IGF-1 gene
expression was quantified using a commercially available
Gene Expression Assay kit (Applied Biosystems, CA).
Expression of IGF-1 mRNA was normalized to β – actin
mRNA expression, and the results were expressed as fold
induction relative to controls.
IGF-1 ELISA
Human IGF-1 level in chondrocyte culture or cartilage
explant media was quantified using a commercially avail-
able Human IGF-1 ELISA kit (R & D Systems) per manu-
facturer's directions.
Quantitation of glycosaminoglycans
At the end of culture period, the culture medium was col-
lected from each group. A 50 µl aliquot of the collected
supernatant from each sample was utilized to estimate the
total glycosaminoglycan (GAG) concentration by a color-
imetric method employing DMMB as previously
described [53]. Color intensity was read spectrophoto-
metrically at 535 nm using the Lambda 25 spectropho-
tometer (Perkin-Elmer, CT) and the values were derived
from a standard curve prepared using different concentra-
tions of chondroitin sulfate. Results are expressed as
micrograms of glycosaminoglycan released per milligram
of cartilage tissue.
Nitric oxide production
Levels of nitrate/nitrite were measured in cartilage explant
and chondrocyte culture media by using the Griess reac-
tion (colorimetric assay) after conversion of the nitrate to
nitrite using a commercially available kit (Molecular
Probes, OR).
Statistical analysis
Cartilage samples from donors were included in control
and test conditions, in other words the influence of sub-
ject variability was negated by including explants or cul-
tures from individual donors in both the control and test
samples. Data was analyzed using the software package,
Instat®, and the analysis included one ay ANOVA followed
by an appropriate post hoc test (Dunnett's). Values are
expressed as mean ± SEM. Differences were considered
significant at P <0.05.
Results
IGF-1 expression and production by human cartilage
Direct activation of IGF-1 gene expression was evaluated
in primary cultures of human chondrocytes by real time
RT-PCR. RNI 249 (50 µg/ml) as well as vincaria (10 µg/
ml) when added to the culture media for 48 hr resulted in
a significant increase in the expression of IGF-1 (Figure 1),
relative to the control, β – actin (P < 0.05). Furthermore,
when RNI 249 and vincaria were combined, these effects
were additive resulting in a nearly 4-fold increase in IGF-
1 gene expression, which was significantly different from
RNI 249 or vincaria alone, as well as basal expression (P <
0.001). Cell viability was unaffected by the treatments
(data no shown).
The potential for RNI 249 to stimulate chondrocyte IGF-1
production was assessed by measurement of IGF-1 in the
culture media of cartilage explants. Explants were exposed
to RNI 249 at 10 and 50 µg/ml for 48 hours at which time
the media was removed for ELISA determination of
human IGF-1 levels (Figure 2). RNI 249 treatment
resulted in a dose-dependent increase in IGF-1 levels that
were significant at the 50 µg/ml dose (P < 0.05). RNI 249
represents the combination of a proprietary Lepidium mey-
enii extract with inert stabilizers as it was noted that the
extract alone had a reduced shelf-life, which is corrected in
the RNI 249 form. IGF-1 production from human carti-
lage explants was also enhanced 67% by vincaria alone
(10  µg/ml, P < 0.05), consistent with the stimulatory
Enhanced expression of IGF-1 gene in human chondrocytes Figure 1
Enhanced expression of IGF-1 gene in human 
chondrocytes. IGF-1 gene expression referenced by the 
activity of β – actin was examined in human chondrocytes (n 
= 3 for all groups) under basal (control) conditions and after 
treatment with RNI 249 50 µg/ml (R50), vincaria 10 µg/ml 
(V10) and their combination (R50 + V10). The * refers to a 
significant difference from control levels (P < 0.05), and the 
** refers to a significant difference from all other groups (P < 
0.001), indicating that the combination of R50 and V10 pro-
duced significantly greater increases in IGF-1 expression than 
either V10 or R50 alone.
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effects of vincaria treatment on IGF-1 gene expression
indicated in Figure 1.
Effects of IL-1β on IGF-1 production
While RNI 249 stimulates basal IGF-1 gene expression
and production in human cartilage, it was necessary to
determine if this action was retained in the presence of IL-
1β. Pro-inflammatory cytokines like TNFα and IL-1β are
known to silence the expression of the IGF-1 gene and
shutdown production in related tissues [31,32,41]. This
ability of IL-1β was confirmed in cartilage explants where
IL-1β (5 ng/ml) exposed explants displayed a complete
suppression of IGF-1 production (Figure 3). Treatment
with either vincaria (10 µg/ml) or RNI 249 (50 µg/ml)
partially restored IGF-1 production (P < 0.01) but interest-
ingly the combination fully restored IGF-1 levels to base-
line, untreated values despite the continued presence of
IL-1β.
IL-1β and GAG release
Culture of cartilage explants to study the effects of cata-
bolic mediators on extracellular matrix (ECM) degrada-
tion is a well established method. We used this method to
study the effects of IL-1β, which induce MMPs and aggre-
canases, on human cartilage ECM degradation and its
modulation by a natural product extract. Exposure of
human cartilage explants to IL-1β resulted in an increase
release of glycosaminoglycans into the media (Figure 4, P
< 0.05). Co-treatment of RNI 249 and IL-1β resulted in a
dose-dependent attenuation of GAG release. Indeed, GAG
release from explants that received the 50 µg/ml dose of
RNI 249 were not statistically significant from untreated
controls (absence of IL-1β) and were significantly
improved over the 10 µg/ml dose and IL-1β alone (P <
0.01).
Vincaria (10 µg/ml) also demonstrated an ability to sup-
press IL-1β induced GAG release (control = 0.141 ± 0.009
µg/mg; IL-1 alone = 0.223 ± 0.010 µg/mg; IL-1β + vincaria
= 0.175 ± 0.010 µg/mg: P < 0.01 for IL-1 vs. control or IL-
1 + vincaria, n = 3). Potential additive effects associated
with the combination of RNI 249 and vincaria was not
tested as the individual components provided full protec-
tion with media GAG levels were not significantly differ-
ent from untreated control explants.
IL-1β and chondrocyte NO production
Media nitrite levels in cartilage explants were used as an
index of nitric oxide production. Both RNI 249 (50 µg/
ml) and vincaria (10 µg/ml) lowered basal nitrite levels
(Figure 5) suggesting that there was a mild inherent acti-
vation of inducible nitric oxide synthase in these surgical
samples. Nevertheless, IL-1β exposure resulted in a
marked increase in nitrite levels consistent with an activa-
tion of inducible nitric oxide synthase. This response was
partially attenuated by vincaria and RNI 249 alone, with
additive effects upon co-treatment (P < 0.01). Similar
results to these described in cartilage explants were noted
in cultured chondrocytes, where RNI 249, vincaria and the
combination reduced IL-1β induced nitrite production (p
< 0.01) but yet nitrite levels remained significantly above
basal nitrite production (data not shown).
Discussion
Circulating levels of IGF-1 primarily reflect the hepatic
production under the influence of growth hormone
(GH). While reduced production of GH and IGF-1 are
associated with aging and joint dysfunction, poor mobil-
ity and increased mortality [36,37,53], the system can be
further uncoupled at the level of signal transduction. Both
the ability of GH to stimulate IGF-1 formation, and the
ability of IGF-1 to activate anabolism can be uncoupled
[34-36]. Altered production of IGF binding proteins that
limit IGF functionality also contribute to the overall tone
of the system [32,43,55-57].
While there are a number of factors including cytokines
and poor nutrition, that are thought to contribute to a dis-
ruption in IGF-1 functionality [58], the present observa-
tions are the first to report that autocrine activation of
IGF-1 gene expression in target tissues is a possible solu-
tion to these problems. We confirmed in human cartilage
explants what has been observed in other tissues that pro-
inflammatory cytokines silence IGF-1 production
[32,33,36]. In the present case this was achieved with IL-
Production of IGF-1 from human cartilage explants as meas- ured by media IGF-1 levels Figure 2
Production of IGF-1 from human cartilage explants 
as measured by media IGF-1 levels. RNI 249 produced a 
dose-dependent increase in media IGF-1 levels, as deter-
mined by ELISA. Only the 50 µg/ml concentration of RNI 249 
produced a significant increase over basal, untreated explants 
(* P < 0.05, n = 6 for all groups).
0
1
2
3
4
5
6
7
8
0
1
2
3
4
5
6
7
8
I
G
F
-
1
 
i
n
 
 
E
x
p
l
a
n
t
 
S
u
p
e
r
n
a
t
a
n
t
s
 
 
 
 
n
g
 
/
m
l
Human Cartilage Explants
Basal
R 10
R 50
*BMC Complementary and Alternative Medicine 2006, 6:13 http://www.biomedcentral.com/1472-6882/6/13
Page 6 of 10
(page number not for citation purposes)
1β, a major determinant of chondrocyte activation and
cartilage destruction [3,4,34,59]. However, this is the first
report that IGF-1 production can be maintained in the
face of these otherwise completely suppressive signals.
The ability of RNI 249, alone and in combination with
vincaria, to maintain IGF-1 levels despite the presence of
IL-1β has the potential to not only limit cartilage destruc-
tion, as was confirmed here with blockade of GAG release,
but also to evoke anabolic actions and repair the joint.
The present study was not focused on a clear demonstra-
tion of an anabolic action. However, there have been
numerous studies reporting that exogenous IGF-1 limits
joint damage and promotes joint repair [59-64].
It is not known how these botanical extracts achieve these
results. We do propose, based on previous observations,
that vincaria is effective by limiting the inhibitory actions
of IL-1β or the suppressive tone of other pro-inflamma-
tory agents. Vincaria is a remarkably potent redox-based
inhibitor of NF-κB and has an IC50 for inhibiting LPS-
induced TNFα production of 10 ng/ml [25,44,46,47]. We
have reported that botanical extracts possessing a similar
mechanism of action [21-23] also display chondroprotec-
tive actions.
On the other hand, while Lepidium meyenii extracts con-
tain catechins [65], they are far weaker antioxidants than
vincaria [40,41,59] and as such are unlikely to operate via
redox-based actions. Lepidium meyenii has primarily been
researched for its ability to promote fertility in males and
females. The breadth of Lepidium meyenii's actions on fer-
tility is impressive and range from increased fetal growth,
reduced miscarriage rates, improvements in conception
rates and increased semen volumes and sperm counts [48-
52]. It is well documented that Lepidium meyenii does not
affect the levels of gonadotrophins, sex steroids or prolac-
tin [48,49], and hence the mechanism of action underly-
ing these pro-fertility effects has remained elusive to date.
As IGF-1 is a critical determinant of fertility and fetal
development we propose that the actions of Lepidium mey-
enii are dictated by a central action of the direct, local acti-
vation of IGF-1 production in target tissues,
independently of growth hormone. What is of critical
interest is that this action can be observed in the presence
of IL-1β, a potent inflammatory agent.
RNI 249 alone, as well as vincaria, was able to block the
increased release of GAG from cartilage explants by IL-1β.
This action of vincaria had been noted previously when
combined with a mineral supplement [24], and similar
effects have also been observed with potent redox-based
anti-inflammatories – green tea epigallocatechin gallate
[22] and anthocyanidin enriched pomegranate fruit
extract [23]. These redox based natural agents appear to
limit cartilage breakdown by blocking the expression, pro-
duction and release of matrix metalloproteases by acti-
vated chondrocytes via a NF-κB and MAPKinase
dependent pathway.
It was of interest to note that nitric oxide production,
another catabolic pathway in cartilage, was less suscepti-
ble to normalization than was GAG release. This follows a
pattern seen with other botanical extracts or nutraceuti-
cals, which note reduced but incomplete blockade of IL-
1β induced nitric oxide production [22-24]. This suggests
that the activation of NO and MMP pathways by IL-1β
vary in their responsiveness to these interventions. How
this may impacts the clinical response in terms of individ-
ual variability and disease targeting remains to be defined.
Studer [66] recently described that nitric oxide modifies
IGF-1 receptor kinase probably via the formation of nitro-
sothiols. This structural modification resulted in altered
functionality with NO blockade enhancing IGF-1 medi-
ated proteoglycan synthesis.
How RNI 249 limits MMP-mediated events (GAG release)
is less clear. A direct suppression of transcription factors
like NF-κB is possible, but remote considering its modest
antioxidant activity. It is possible that the elevation of
IGF-1 production by RNI 249 exerts a negative influence
IGF-1 production from human cartilage explants in response  to IL-1β, vincaria and RNI 249 and their combination Figure 3
IGF-1 production from human cartilage explants in 
response to IL-1β, vincaria and RNI 249 and their 
combination. Control, untreated cartilage explants (n = 6) 
release a defined amount of IGF-1 into the bathing media. 
However, in IL-1β (5 ng/ml) treated explants IGF-1 levels 
were immeasurable (n = 6). Co-treatment with either vin-
caria 10 µg/ml (V10, n=3), or RNI 249 50 µg/ml (R50, n = 6), 
partially restored IGF-1 production. The combination of vin-
caria and RNI 249 (IL-1 + V + R, n = 3) produced additive 
effects that resulted in the restoration of IGF-1 levels to con-
trol values despite the presence of IL-1β. The * denotes a sig-
nificant difference from all other groups (P < 0.01).
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on cartilage catabolism as described with exogenous IGF-
1 [54,61-63]. However, as we have not performed studies
to demonstrate that RNI 249 actions can be blocked by
inhibitors of IGF-1 signal transduction, these events must
be considered associations and not causations. It is not
clear if autocrine activation of IGF-1 can be blocked by cir-
culating IGF-1 binding proteins and so causative proof-of-
principle studies are not simple to execute.
There have numerous and diverse approaches employed
to enhance the anabolic actions of IGF-1 ranging from
increasing production or independently enhancing func-
tionality. Haupt et al [55] using viral gene transfer studies
to synoviocytes corrected articular cartilage degradation in
vitro. They observed that by combining IGF-1 with an IL-
1 receptor antagonist protein they could both increase
proteoglycan production and decrease catabolism via
reduced MMP synthesis. They proposed that a combina-
tion approach of combining anabolic growth factors with
catabolic blockers to prevent matrix degradation would be
ideal for healing destructive joint diseases. This is concep-
tually similar to the approach used in the present study –
enhanced autocrine production of IGF-1 and suppression
of inhibitory cytokine tone.
Madry et al [64] demonstrated that IGF-1 gene transfer
was effective healing for traumatic cartilage repair. Using
an in vivo model of cartilage loss in rabbits, Tuncel et al
[63] noted that collagen sponges impregnated with
recombinant IGF-1 accelerated cartilage restoration.
Another approach was described by De Ceuninck et al
[55], who noted that disruption of IGF-1 binding to the
inhibitory binding proteins via small molecules, resulting
in the release of free IGF-1, restores the anabolic response
of human chondrocytes. This suggests that a critical regu-
latory site of IGF-1 bioactivity is the inactivation of circu-
lating IGF-1 by binding proteins. With the appreciation
that increased levels of IGF-1 binding proteins have been
observed in osteoarthritic cartilage [57] one needs to con-
sider if the optimal approach is to raise circulating IGF-1
levels or alternatively promote local production in an
autocrine manner.
While these reports collectively demonstrate that IGF-1
can promote healing and joint restoration and that a mul-
titude of potential approaches to the problem are possi-
ble, few are likely to have an immediate impact on health
care. By contrast, the combination of the natural products
RNI 249 and vincaria has already been commercialized in
the USA and Canada under the name "Reparagen" and so
it can be considered an immediate and current option in
contrast to the elegant but commercially distant
approaches of gene transfer or other pharmacological
approaches.
A clear limitation of the present study is that it has been
performed in vitro, albeit with human cartilage speci-
mens, and therefore it would be appropriate to hold res-
ervations that the present observations may not be
translated into the in vivo setting or effective with oral
intake. However, we consider that outcomes as being
unlikely. In the case of vincaria it has already been shown
that it is effective in treating osteoarthritis of the knee in
humans with oral administration at the remarkably low
dose of only 100 mg/day [47]. Additionally, vincaria has
displayed oral bioactivity in animal models of inflamma-
tion [25,44]. RNI 249 is also likely to be orally active in
terms of enhanced IGF-1 production as it is orally active
for anabolic actions in farmed fish (unpublished observa-
tions) and Lepidium meyenii and related extracts have well
defined effects in pregnancy and male fertility upon oral
administration [48-51]; effects that are entirely consistent
with enhanced IGF-1 production. However, an osteoar-
thritis orientated clinical trial would address these issues
and place the present innovation in an appropriate per-
spective where one could also address potential benefits
to the joint as a whole, including skeletal muscle and
bone.
Conclusion
Joint inflammation and loss of cartilage matrix are not
well correlated. Often therapies provide symptomatic
Normalization of IL-1β enhanced glycosaminoglycan release  from human cartilage explants by RNI 249 Figure 4
Normalization of IL-1β enhanced glycosaminoglycan 
release from human cartilage explants by RNI 249. 
Treatment of human cartilage explants (n = 6) with IL-1β (5 
ng/ml) results in the release of glycosaminoglycans (GAG) 
into the media. Administration of RNI 249 produced a dose-
dependent decrease of IL-1β induced GAG release that was 
significant at the 10 µg/ml (R10, * P < 0.05) and 50 µg/ml (** 
P < 0.01) concentrations. The level of GAG release from 
control, untreated explants was indistinguishable from those 
explants treated with IL-1β + RNI 249 (50 µg/ml).
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relief but fail to restore architecture. The present observa-
tions with a novel South American medicinal plant com-
bination that simultaneously addresses catabolic and
anabolic activities, suggests that it is possible to directly
activate local, chondrocyte IGF-1 production, even in the
presence of IL-1β. This action has the potential to provide
a therapeutic approach that not only limits joint inflam-
mation and destruction but to promote joint restoration.
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